Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-06-21
2011-06-21
Zucker, Paul A (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S604000, C564S084000, C564S087000
Reexamination Certificate
active
07964643
ABSTRACT:
The present invention pertains to compounds of the following formula (wherein RP, r, q, RN, Ralk, and Q are as defined herein) and compositions comprising those compounds. The compounds may be used to inhibit osteoclast survival, formation, and/or activity; to inhibit conditions mediated by osteoclasts and/or characterised by bone resorption; in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease; and/or in the treatment of conditions associated with inflammation or activation of the immune system.
REFERENCES:
patent: 5760028 (1998-06-01), Jadhav et al.
patent: 6159995 (2000-12-01), Thorwart et al.
patent: 6451824 (2002-09-01), Thorwart et al.
patent: 2003/0144292 (2003-07-01), Natchus et al.
patent: 2005/0119305 (2005-06-01), Naka et al.
patent: 10 46 220 (1958-12-01), None
patent: 0 877 018 (1998-11-01), None
patent: 0 877 019 (1998-11-01), None
patent: 0 960 882 (1999-12-01), None
patent: 1 491 190 (2004-01-01), None
patent: 1 431 267 (2004-06-01), None
patent: 11-246527 (1999-09-01), None
patent: 96/37492 (1996-11-01), None
patent: 97/16433 (1997-05-01), None
patent: 97/33887 (1997-09-01), None
patent: 98/03166 (1998-01-01), None
patent: 98/23608 (1998-06-01), None
patent: 98/43962 (1998-10-01), None
patent: 98/50342 (1998-11-01), None
patent: 99/37621 (1999-07-01), None
patent: 99/42443 (1999-08-01), None
patent: 01/16137 (2001-03-01), None
patent: 01/90077 (2001-11-01), None
patent: 02/060867 (2002-08-01), None
patent: 02/074298 (2002-09-01), None
patent: 03/037321 (2003-05-01), None
patent: 2004/022561 (2004-03-01), None
patent: 2004/098582 (2004-11-01), None
Armour K.J., et al., 2001, “Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026), ”Arthritis and Rheumatism, vol. 44, No. 9, pp. 2185-2192.
Augstein, J., et al., 1965, “Some cardiovascular effects of a series of aryloxyalkylamines 1”,J. Med. Chem., vol. 8, pp. 356-367.
Coxon, F.P., et al., 2000, “Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298,”J.Bone Miner.Res., vol. 15, pp. 1467-1476.
Degenhardt, C.R., et al., 1986, “Synthesis of Ethenylidenebis(phosphonic acid) and its Tetraalkyl Esters,”J. Org. Chem., vol. 51, pp. 3488-3490.
Eberhard, A., et al., 1965, “Hydrolysis of Phostonates,”J. Amer. Chem. Soc., vol. 87, pp. 253-260.
Ha-Duong, N-T, et al, 2001, “Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily”,J. Med. Chem., vol. 44, pp. 3622-3631.
Herczegh, P., et al, 2002, “Osteoadsorptive Bisphosphonate Derivatives of Fluoroquinolone Antibacterials,”J. Med. Chem., vol. 45, pp. 2338-2341.
Hughes, D.E., et al., 1997, “Apoptosis in bone physiology and disease,”Molecular Pathology, vol. 50, pp. 132-137.
Kong, Y.Y., et al., 1999, “OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis,”Nature, vol. 397, pp. 315-323.
Luckman, et al., 1998, “Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages,”J. Bone Miner.Res., vol. 13, pp. 1668-1678.
MacPherson, H; et al., 1999, “Expression and functional role of nitric oxide synthase isoforms in human osteoblast-like cells,”Bone, vol. 24, pp. 179-185.
Mundy, G.R., 1996, “Chapter 1: Bone Remodeling”, inBone Remodeling and its disorders(2nd edition), London, (Ed. Martin Dunitz), pp. 1-11.
Nociari, M.N., et al., 1998, “A novel one-step, highly sensitive fluorimetric assay to evaluate cell-mediated cytotoxicity,”Journal of Immunological Methods, vol. 213, pp. 157-167.
Nyormoi, O., et al., 2003, “An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells”,Cell Death and Differentiation, vol. 10, pp. 558-569.
Peyman, A., et al., 2001, “ανβ3antagonists based on a central thiophene scaffold”,Bio. &Med. Chem. Letters, Vo. 11, pp. 2011-2015.
Raisz, L.G., 1988, “Local and systemic factors in the pathogenesis of osteoporosis,”N. Engl. J. Med., vol. 318, pp. 818-828.
Ralston, S.H., 1997, “Science, Medicine and the Future: Osteoporosis,”Br. Med. J., vol. 315, pp. 469-472.
Rodan, G.A., et al., 1997, “The missing bone,”Cell, vol. 89, pp. 677-680.
Takahashi, N.; et al., 1988, “Osteoblastic cells are involved in osteoclast formation,”Endocrinology, vol. 123, pp. 2600-2602.
Takasuka, M., et al., 1991, “FTIR spectral study of intramolecular hydrogen bonding in thromboxane A2receptor antagonist S-145 and related compounds. 3. Conformation and activity of S-145 analogues”,J. Med. Chem., vol. 34, pp. 1885-1891.
van't Hof, R.J., et a;., 1997, “Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity,”J. Bone&Miner. Res., vol. 12, pp. 1797-1804.
Yasuda, H., et al, 1998, “Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro”,Endocrinology, vol. 139, pp. 1329-1337.
Greig Iain Robert
Mohamed Aymen Ibrahim Idris
Ralston Stuart Hamilton
Van 'T Hof Robert Jurgen
Nixon & Vanderhye P.C.
The University Court of the University of Aberdeen
Zucker Paul A
LandOfFree
Aryl alkyl sulfonamides as therapeutic agents for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl alkyl sulfonamides as therapeutic agents for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl alkyl sulfonamides as therapeutic agents for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2696190